Oslo, Norway, 24 July 2009 - Algeta ASA, the cancer therapeutics company, announces it has appointed Dr. Gillies O'Bryan-Tear as Chief Medical Officer.
Dr. O'Bryan-Tear has more than 20 years' pharmaceutical industry experience in senior roles managing and advising on the clinical development and registration of new drugs and vaccines. He has extensive development and clinical knowledge in oncology and has developed and successfully launched major oncology products. He has worked both as an independent consultant to and in-house for a number of leading biotechnology and pharmaceutical companies. He is the former Vice President of Global Clinical R&D at GlaxoSmithKline Biologicals, spent two years as Interim Medical Director for Genzyme UK, and was previously medical director in the UK and Northern Europe for Bristol-Myers Squibb.
Dr. O'Bryan-Tear has been Acting CMO for Algeta since March 2009 and has been a consultant to the Company on the clinical development of Alpharadin since 2004. Alpharadin (radium-223) is a novel alpha-pharmaceutical and Algeta's lead cancer therapeutic in a global phase III clinical trial (ALSYMPCA) designed to confirm its efficacy and safety as a targeted treatment for bone metastases in patients with advanced, hormone-refractory prostate cancer.
Andrew Kay, CEO of Algeta, said, "Gillies brings a wealth of clinical development and regulatory expertise to Algeta as well as a deep understanding of our lead alpha-pharmaceutical candidate Alpharadin and its development so far. He is an important addition to the senior management team and his experience will be crucial to the Company as we progress the phase III ALSYMPCA study with Alpharadin and step up preparations for the global commercialization of this potential blockbuster."
Dr. O'Bryan-Tear said, "I have been extremely impressed with the clinical data with Alpharadin to date, which clearly show Alpharadin has the potential to become a very important treatment for patients whose cancer has spread to the bones. I know of no other treatment that combines the exquisite targeting of Alpharadin for bone metastases with the benign side effect profile we have seen. Alpharadin has been shown to prolong survival and to enhance quality of life for patients with advanced disease. The next couple of years are going to be an exciting period in the Company's development and I am delighted to be a part of it."
Dr. O'Bryan-Tear is a UK-trained physician who earned his M.D. at the Universities of Cambridge and London, and has an MBA from Cranfield School of Management. He is an advisor to Advent Venture Partners.